Skip to main content

Table 1 Demographic and clinical characteristics of patients with Crohn’s disease at baseline

From: Current diagnosis and management of Crohn’s disease in China: results from a multicenter prospective disease registry

VariableTotalInland cityCoastal cityP value
N (%)499191 (38.3%)308 (61.7%) 
Age at enrollment (years), mean (SD)32.3 (11.43)34.3 (13.03)31.1 (10.14)0.0022
Male, n (%)348 (69.7%)138 (72.3%)210 (68.2%) 
Ethnicity, n (%)
 Chinese Han495 (99.2%)187 (97.9%)308 (100.0%) 
 Other Chinese minority4 (0.8%)4 (2.1%)0 
BMI (kg/m2), mean (SD)19.10 (3.198)18.80 (2.676)19.29 (3.479) 
Nicotine use history, n (%)   0.0036
 N442165277 
 Never used382 (86.4%)132 (80.0%)250 (90.3%) 
 Current user36 (8.1%)17 (10.3%)19 (6.9%) 
 Former user24 (5.4%)16 (9.7%)8 (2.9%) 
Alcohol use history, n (%)   0.0023
 N443166277 
 Never used401 (90.5%)143 (86.1%)258 (93.1%) 
 Current user22 (5.0%)8 (4.8%)14 (5.1%) 
 Former user20 (4.5%)15 (9.0%)5 (1.8%) 
Medical history reported, n (%)
 Any medical history180 (36.1%)76 (39.8%)104 (33.8%) 
 Hepatitis B19 (3.8%)7 (3.7%)12 (3.9%) 
 Appendicitis10 (2.0%)5 (2.6%)5 (1.6%) 
 Hypertension8 (1.6%)3 (1.6%)5 (1.6%) 
 Nephrolithiasis10 (2.0%)7 (3.7%)3 (1.0%) 
CD-related surgery history, n (%)119 (23.8%)51 (26.7%)68 (22.1%)0.2071
Perianal disease related surgery, n (%)79 (15.8%)21 (11.0%)58 (18.8%)0.0023
Family history of IBD, n (%)
 N624 
 Crohn’s disease5 (83.3%)2 (100%)3 (75.0%) 
 Ulcerative colitis1 (16.7%)01 (25.0%) 
Age at disease onset (years), n (%)   0.0291
  ≤ 1629 (5.8%)15 (7.9%)14 (4.5%) 
 17–39401 (80.4%)142 (74.3%)259 (84.1%) 
  ≥ 4069 (13.8%)34 (17.8%)35 (11.4%) 
Age at initial diagnosis (years), n (%)   0.0083
  ≤ 166 (1.2%)4 (2.1%)2 (0.6%) 
 17–39418 (83.8%)148 (77.5%)270 (87.7%) 
  ≥ 4075 (15.0%)39 (20.4%)36 (11.7%) 
Time from disease onset to initial diagnosis (months), mean (SD)32.0 (46.43)39.9 (58.84)27.0 (35.93)0.0255
Location, n (%)   < 0.0001
 N493190303 
 L1137 (27.8%)69 (36.3%)68 (22.4%) 
 L271 (14.4%)38 (20.0%)33 (10.9%) 
 L3277 (56.2%)82 (43.2%)195 (64.4%) 
 L48 (1.6%)1 (0.5%)7 (2.3%) 
Behavior, n (%)   < 0.0001
 N495190305 
 B1247 (49.9%)110 (57.9%)137 (44.9%) 
 B2148 (29.9%)45 (23.7%)103 (33.8%) 
 B3100 (20.2%)35 (18.4%)65 (21.3%) 
 Perianal disease144 (29.1%)32 (16.8%)112 (36.7%) 
Crohn’s Disease Activity Index at baseline, n (%)   0.0094
 N1658085 
  < 15081 (49.1%)37 (46.3%)44 (51.8%) 
 150–22043 (26.1%)28 (35.0%)15 (17.6%) 
 221–40039 (23.6%)13 (16.3%)26 (30.6%) 
  > 4002 (1.2%)2 (2.5%)0 
Crohn’s disease treatment information at baseline, n (%)
 Any Crohn’s disease treatment441 (88.4%)161 (84.3%)280 (90.9%)0.0308
 Immunomodulators207 (41.5%)78 (40.8%)129 (41.9%)0.8179
 Anti-TNF agents164 (32.9%)50 (26.2%)114 (37.0%)0.0123
 Aminosalicylates103 (20.6%)47 (24.6%)56 (18.2%)0.0847
 Steroids99 (19.8%)53 (27.7%)46 (14.9%)0.0005
 Enteral nutrition69 (13.8%)6 (3.1%)63 (20.5%)< 0.0001
 Antibiotics65 (13.0%)6 (3.1%)59 (19.2%)< 0.0001
 Anti-tuberculosis27 (5.4%)1 (0.5%)26 (8.4%)< 0.0001
 Anti-hepatitis3 (0.6%)2 (1.0%)1 (0.3%)0.5613
 Other agentsa115 (23.0%)7 (3.7%)108 (35.1%)< 0.0001
  1. B1 non-stricturing non-penetrating, B2 stricturing, B3 penetrating, BMI body mass index, CD Crohn’s disease, IBD inflammatory bowel disease, L1 terminal ileum, L2 colon, L3 ileocolon, L4 upper gastrointestinal tract, n total number of participants in a subset, N total sample size, SD standard deviation, TNF tumor necrosis factor
  2. aOther agents including traditional Chinese medicine, et al